UA87109C2 - USE OF HIF PROLYLHYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIAS AND iron deficiency - Google Patents

USE OF HIF PROLYLHYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIAS AND iron deficiency

Info

Publication number
UA87109C2
UA87109C2 UAA200600150A UAA200600150A UA87109C2 UA 87109 C2 UA87109 C2 UA 87109C2 UA A200600150 A UAA200600150 A UA A200600150A UA A200600150 A UAA200600150 A UA A200600150A UA 87109 C2 UA87109 C2 UA 87109C2
Authority
UA
Ukraine
Prior art keywords
prolylhydroxylase
inhibitor
treatment
anemia
iron deficiency
Prior art date
Application number
UAA200600150A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Стефен Дж. Клаус
Кристофер Дж. Молино
Томас Б. Нефф
Фолькмар Гуенцлер-Пукалл
Паробок Інгрид Лансетмо
Тодд В. Сили
Роберт С. Стефенсон
Original Assignee
Фиброген, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фиброген, Инк. filed Critical Фиброген, Инк.
Publication of UA87109C2 publication Critical patent/UA87109C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the methods for treatment or prevention of anemia caused by chronic disease, iron deficiency, microcytosis or microcytic anemia, anemia, connected with cytokine activity, anemia, which is difficult to treat by erythropoietin (ЕРО), which is administered exogenously using efficient amount ofHIF prolylhydroxylase inhibitor, which represents the structural mimetic of 2-oxoglutarate.
UAA200600150A 2003-06-06 2004-06-04 USE OF HIF PROLYLHYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIAS AND iron deficiency UA87109C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47670403P 2003-06-06 2003-06-06

Publications (1)

Publication Number Publication Date
UA87109C2 true UA87109C2 (en) 2009-06-25

Family

ID=36908152

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200600150A UA87109C2 (en) 2003-06-06 2004-06-04 USE OF HIF PROLYLHYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIAS AND iron deficiency

Country Status (4)

Country Link
CN (1) CN1816327B (en)
NO (1) NO20171470A1 (en)
UA (1) UA87109C2 (en)
ZA (1) ZA200509279B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334682B1 (en) * 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037813T2 (en) * 1999-06-04 2009-01-15 Dana-Farber Cancer Institute, Inc., Boston IDENTIFICATION OF SUBSTANCES THAT MODIFY TRANSCRIPTIONAL ANSWERS TO HYPOXIA

Also Published As

Publication number Publication date
NO20171470A1 (en) 2006-01-06
CN1816327A (en) 2006-08-09
ZA200509279B (en) 2007-11-28
CN1816327B (en) 2010-09-08

Similar Documents

Publication Publication Date Title
NO20060100L (en) Use of HIF alpha stabilizers to increase erythropoiesis
WO2005007192A3 (en) Cytoprotection through the use of hif hydroxylase inhibitors
WO2006133391A3 (en) Improved treatment for anemia using a hif-alpha stabilising agent
WO2003002595A3 (en) Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
WO2006048750A3 (en) Novel compounds of substituted and unsubstituted adamantyl amides
MY133667A (en) Quinazoline ditosylate salt compounds
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
IL151695A0 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
NO20032625D0 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
ATE521608T1 (en) GLUCOKINASE ACTIVATORS
BG106020A (en) Inhibitors of impdh enzyme
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
ATE409035T1 (en) SUBSTITUTED PYRROLINES AS KINASE INHIBITORS
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
RS13204A (en) Combination therapy for the treatment of cancer
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE445406T1 (en) USE OF IRON(III) COMPLEX COMPOUNDS
TW200726763A (en) Novel compound
DK1463735T3 (en) Imidazo-2,1-B -1,3,4-thiadiazole sulfonamides
EP1667685A4 (en) Quinazoline potassium channel inhibitors
DE602004028493D1 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
MXPA03007653A (en) Use of lp82 to treat hematopoietic disorders.
UA87109C2 (en) USE OF HIF PROLYLHYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIAS AND iron deficiency
HUP0200288A2 (en) Use of pde4 for treating copd
ATE423102T1 (en) 4-SUBSTITUTED-5-CYANO-1H-PYRIMIDINE-6-(TH)IONES AS A GSK-3 INHIBITOR